Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 6:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 16,296 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Condition Clear all
Not listed Not applicable Interventional

Consciousness-based Ayurveda Lifestyle Program for Improving Quality of Life in Survivors of Breast Cancer

NCT05743023
View directory record Official record
Conditions
Breast Cancer Survivors
Interventions
Ayurvedic lifestyle protocol
Behavioral
Lead sponsor
Robert Schneider, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Richmond, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2023 · Synced Oct 29, 2026, 6:32 PM EDT
Completed Phase 4 Interventional Results available

Use of Santyl in Diabetic Foot Ulcers

NCT02581488
View directory record Official record
Conditions
Diabetic Foot, Foot Ulcer, Diabetic
Interventions
Santyl, Product containing silver
Biological · Other
Lead sponsor
Smith & Nephew, Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
11
States / cities
Sylmar, California • Melbourne, Florida • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 29, 2026, 6:32 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris

NCT01019603
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene, Tazaroc Gel
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
12 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Oct 29, 2026, 6:32 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenail

NCT00453271
View directory record Official record
Conditions
Onychomycosis
Interventions
NB-002, Vehicle control
Drug
Lead sponsor
NanoBio Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
443 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
13
States / cities
Miami, Florida • Boise, Idaho • Evansville, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated May 23, 2013 · Synced Oct 29, 2026, 6:32 PM EDT
Recruiting Phase 3 Interventional

Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)

NCT07863193
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Denifanstat, Placebo
Drug · Other
Lead sponsor
Sagimet Biosciences Inc.
Industry
Eligibility
12 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
23
States / cities
Bryant, Arkansas • Fremont, California • Santa Ana, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 29, 2026, 6:32 PM EDT
Terminated Phase 2 Interventional Results available

An Extension Study to Determine Safety and Efficacy for Pediatric Patients With MPS Type IIIA Disease Who Participated in Study HGT-SAN-093.

NCT02350816
View directory record Official record
Conditions
Sanfilippo Syndrome, Mucopolysaccharidosis (MPS)
Interventions
HGT-1410
Drug
Lead sponsor
Shire
Industry
Eligibility
12 Months to 48 Months
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Minneapolis, Minnesota • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 29, 2026, 6:32 PM EDT
Completed Not applicable Interventional

Acupuncture for Anxiety in Women With Breast Cancer: A Feasibility Study

NCT00322504
View directory record Official record
Conditions
Breast Cancer
Interventions
Accupuncture
Procedure
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 7, 2010 · Synced Oct 29, 2026, 6:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study to Compare the Blood Levels of Abatacept Manufactured at Lonza Biologics to the Blood Levels of Abatacept Manufactured at the Devens, Massachusetts (MA) Facility of Bristol-Myers Squibb

NCT01439204
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept (BMS-188667)
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
223 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 19, 2014 · Synced Oct 29, 2026, 6:32 PM EDT
Completed Not applicable Interventional

FLARE Lupus Research Study Systemic Lupus Erythematosus

NCT03426384
View directory record Official record
Conditions
System; Lupus Erythematosus
Interventions
Mymee Program
Behavioral
Lead sponsor
Mymee Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Oct 29, 2026, 6:32 PM EDT
Recruiting Phase 1Phase 2 Interventional

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

NCT07558733
View directory record Official record
Conditions
HR+ HER2- Breast Cancer
Interventions
Serabelisib, Sapanisertib, Fulvestrant
Drug
Lead sponsor
Faeth Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
7
States / cities
Los Angeles, California • Lone Tree, Colorado • Springfield, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 29, 2026, 6:32 PM EDT
Completed Phase 2 Interventional

A Study of Adalimumab to Treat Sarcoidosis of the Skin

NCT00274352
View directory record Official record
Conditions
Sarcoidosis
Interventions
adalimumab
Drug
Lead sponsor
Pariser, Robert J., M.D.
Other
Eligibility
18 Years to 89 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated May 22, 2013 · Synced Oct 29, 2026, 6:32 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Examining the Immunological Process of Autoimmune Patients

NCT02123147
View directory record Official record
Conditions
Sjogren's Syndrome, Autoimmune Diseases, Dry Eyes, Dry Mouth
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
9 Years to 21 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Oct 29, 2026, 6:32 PM EDT
Completed Phase 3 Interventional Results available

Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

NCT03745638
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib Cream, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 29, 2026, 6:32 PM EDT
Terminated Phase 2 Interventional Results available

Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery

NCT01533948
View directory record Official record
Conditions
Extraocular Extension Melanoma, Metastatic Intraocular Melanoma, Recurrent Intraocular Melanoma, Recurrent Melanoma, Stage IIIA Intraocular Melanoma, Stage IIIA Melanoma, Stage IIIB Intraocular Melanoma, Stage IIIB Melanoma, Stage IIIC Intraocular Melanoma, Stage IIIC Melanoma, Stage IV Intraocular Melanoma, Stage IV Melanoma
Interventions
axitinib, laboratory biomarker analysis
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 9, 2018 · Synced Oct 29, 2026, 6:32 PM EDT
Not yet recruiting Phase 2 Interventional

Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma

NCT06708455
View directory record Official record
Conditions
Malignant Melanoma With Metastasis, Malignant Melanoma, Malignant Melanoma Stage IIIc, Malignant Melanoma Stage IV
Interventions
RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy
Biological · Drug
Lead sponsor
Rapa Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 29, 2026, 6:32 PM EDT
Completed Not applicable Interventional

Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition

NCT05721326
View directory record Official record
Conditions
Genetic Predisposition to Disease, Breast Cancer Female, Ovarian Cancer, Hereditary Breast and Ovarian Cancer, Hereditary Cancer Syndrome, Hereditary Diseases, Gene Mutation-Related Cancer
Interventions
Sequential EHR Communications
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
25 Years to 100 Years · Female only
Enrollment
1,283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 29, 2026, 6:32 PM EDT
Completed Phase 1 Interventional

A Study of ASN007 in Patients With Advanced Solid Tumors

NCT03415126
View directory record Official record
Conditions
Cancer, Malignancy, Neoplasia, Neoplasm, Neoplasm Metastasis, Colon Cancer, Colonic Neoplasms, Colon Cancer Liver Metastasis, Metastatic Cancer, Metastatic Melanoma, Metastatic Colon Cancer, Metastatic Lung Cancer, Non Small Cell Lung Cancer Metastatic, Pancreatic Cancer, Pancreas Cancer, Pancreas Adenocarcinoma, Pancreas Neoplasm, Metastatic Nonsmall Cell Lung Cancer, Metastatic Pancreatic Cancer
Interventions
ASN007: ascending doses, ASN007 RD
Drug
Lead sponsor
Asana BioSciences
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
5
States / cities
Tampa, Florida • Boston, Massachusetts • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2020 · Synced Oct 29, 2026, 6:32 PM EDT
Recruiting Phase 1 Interventional

CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)

NCT04318678
View directory record Official record
Conditions
AML/MDS, B-ALL, T-ALL, BPDCN
Interventions
CD123-CAR T, Cyclophosphamide, Fludarabine, Mesna, Rituximab
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
2
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 29, 2026, 6:32 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

NCT07115043
View directory record Official record
Conditions
Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer/Gastroesophageal Junction Cancer, High Grade Serous Ovarian Carcinoma
Interventions
AZD6750, rilvegostomig
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
6
States / cities
Grand Rapids, Michigan • St Louis, Missouri • Pittsburgh, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 29, 2026, 6:32 PM EDT
Completed Not applicable Interventional

Intergenerational Transmission of Traumatic Stress

NCT05264415
View directory record Official record
Conditions
Stress, Psychological, Stress Disorders, Traumatic, Emotion Regulation, Behavior, Child, Emotional Stress, Trauma, Psychological, Anxiety, Depression, Coping Skills, Parent-Child Relations, Parenting
Interventions
Families OverComing Under Stress (FOCUS) for Early Childhood (FOCUS-EC), Parenting Education Website
Behavioral · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
3 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 29, 2026, 6:32 PM EDT
Completed No phase listed Observational Results available

Evaluation of BIS for Quantification of Lymphedema

NCT01544335
View directory record Official record
Conditions
Breast Cancer
Interventions
Bioimpedance Spectroscopy
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Oct 29, 2026, 6:32 PM EDT
Completed Phase 2 Interventional

Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer

NCT00003408
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor
Interventions
aldesleukin, recombinant interferon alfa, sargramostim
Biological
Lead sponsor
Cancer Treatment Centers of America
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Zion, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 26, 2013 · Synced Oct 29, 2026, 6:32 PM EDT
Withdrawn Phase 3 Interventional

Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer

NCT02929576
View directory record Official record
Conditions
Breast Cancer
Interventions
Enzalutamide, Placebo, Paclitaxel
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
6
States / cities
Topeka, Kansas • Metairie, Louisiana • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Oct 29, 2026, 6:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

BC-DAISY: A Breast Cancer Decision Aid System

NCT00347568
View directory record Official record
Conditions
Breast Cancer
Interventions
TX-plore
Device
Lead sponsor
Rhode Island Hospital
Other
Eligibility
21 Years to 75 Years · Female only
Enrollment
195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced Oct 29, 2026, 6:32 PM EDT